Logo image of CLYM

CLIMB BIO INC (CLYM) Stock Overview

NASDAQ:CLYM - US28658R1068 - Common Stock

2.285 USD
-0.04 (-1.93%)
Last: 8/27/2025, 8:00:01 PM
2.33 USD
+0.04 (+1.97%)
After Hours: 8/27/2025, 8:00:01 PM

CLYM Key Statistics, Chart & Performance

Key Statistics
52 Week HighN/A
52 Week LowN/A
Market Cap154.83M
Shares67.76M
Float62.20M
Yearly DividendN/A
Dividend YieldN/A
EPS(TTM)-0.69
PEN/A
Fwd PEN/A
Earnings (Next)N/A N/A
IPO08-10 2021-08-10
Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology


CLYM short term performance overview.The bars show the price performance of CLYM in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 20 40 60 80

CLYM long term performance overview.The bars show the price performance of CLYM in the last 1, 2 and 3 years. 1 year 2 years 3 years

The current stock price of CLYM is 2.285 USD. In the past month the price increased by 50.33%.

CLIMB BIO INC / CLYM Daily stock chart

CLYM Competitors/Peers

The largest stocks on the US markets in the "Biotechnology" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
ABBV ABBVIE INC 19.65 367.55B
AMGN AMGEN INC 13.2 155.03B
GILD GILEAD SCIENCES INC 14.72 141.35B
VRTX VERTEX PHARMACEUTICALS INC 22.97 99.76B
REGN REGENERON PHARMACEUTICALS 12.86 62.21B
ALNY ALNYLAM PHARMACEUTICALS INC N/A 59.53B
ARGX ARGENX SE - ADR 76.37 43.33B
ONC BEONE MEDICINES LTD-ADR 6.06 35.68B
INSM INSMED INC N/A 28.44B
BNTX BIONTECH SE-ADR N/A 24.76B
NTRA NATERA INC N/A 22.38B
BIIB BIOGEN INC 8.52 19.99B

About CLYM

Company Profile

CLYM logo image Climb Bio, Inc. operates as a clinical-stage biotechnology company. The company is headquartered in Wellesley Hills, Massachusetts and currently employs 17 full-time employees. The company went IPO on 2021-08-10. The firm is focused on developing therapeutics for patients with immune-mediated diseases. The Company’s lead product candidate, budoprutug, is an anti-CD19 monoclonal antibody designed to deplete CD19-positive B cells, including antibody-secreting cells, in order to directly reduce pathogenic autoantibodies. The reduction of autoantibodies has the potential to be disease-modifying in autoantibody-driven diseases, such as systemic lupus erythematosus, immune thrombocytopenia, and membranous nephropathy. The budoprutug is in a Phase Ib/IIa clinical trial. The firm is also developing CLYM116, an anti-APRIL antibody, in investigational new drug applications (IND)-enabling studies for IgA nephropathy (IgAN).

Company Info

CLIMB BIO INC

20 William Street, Suite 145

Wellesley Hills MASSACHUSETTS US

Employees: 17

CLYM Company Website

CLYM Investor Relations

Phone: 18668572596

CLIMB BIO INC / CLYM FAQ

What is the stock price of CLIMB BIO INC today?

The current stock price of CLYM is 2.285 USD. The price decreased by -1.93% in the last trading session.


What is the ticker symbol for CLIMB BIO INC stock?

The exchange symbol of CLIMB BIO INC is CLYM and it is listed on the Nasdaq exchange.


On which exchange is CLYM stock listed?

CLYM stock is listed on the Nasdaq exchange.


What is the price forecast or stock price prediction for CLIMB BIO INC stock?

8 analysts have analysed CLYM and the average price target is 9.18 USD. This implies a price increase of 301.75% is expected in the next year compared to the current price of 2.285. Check the CLIMB BIO INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is CLIMB BIO INC worth?

CLIMB BIO INC (CLYM) has a market capitalization of 154.83M USD. This makes CLYM a Micro Cap stock.


How many employees does CLIMB BIO INC have?

CLIMB BIO INC (CLYM) currently has 17 employees.


What are the support and resistance levels for CLIMB BIO INC (CLYM) stock?

CLIMB BIO INC (CLYM) has a support level at 1.9 and a resistance level at 2.38. Check the full technical report for a detailed analysis of CLYM support and resistance levels.


Should I buy CLIMB BIO INC (CLYM) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does CLIMB BIO INC (CLYM) stock pay dividends?

CLYM does not pay a dividend.


What is the Price/Earnings (PE) ratio of CLIMB BIO INC (CLYM)?

CLIMB BIO INC (CLYM) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.69).


What is the Short Interest ratio of CLIMB BIO INC (CLYM) stock?

The outstanding short interest for CLIMB BIO INC (CLYM) is 2.11% of its float. Check the ownership tab for more information on the CLYM short interest.


CLYM Technical Analysis

ChartMill assigns a technical rating of 7 / 10 to CLYM.


Chartmill TA Rating
Chartmill Setup Rating

CLYM Fundamental Analysis

ChartMill assigns a fundamental rating of 3 / 10 to CLYM. While CLYM has a great health rating, there are worries on its profitability.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

CLYM Financial Highlights

Over the last trailing twelve months CLYM reported a non-GAAP Earnings per Share(EPS) of -0.69. The EPS increased by 67.71% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -24.3%
ROE -25.17%
Debt/Equity 0
Chartmill High Growth Momentum
EPS Q2Q%92.91%
Sales Q2Q%N/A
EPS 1Y (TTM)67.71%
Revenue 1Y (TTM)N/A

CLYM Forecast & Estimates

8 analysts have analysed CLYM and the average price target is 9.18 USD. This implies a price increase of 301.75% is expected in the next year compared to the current price of 2.285.


Analysts
Analysts87.5
Price Target9.18 (301.75%)
EPS Next Y52.71%
Revenue Next YearN/A

CLYM Ownership

Ownership
Inst Owners84.99%
Ins Owners0.37%
Short Float %2.11%
Short Ratio2.73